Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites (Q34621433)

3 August 2017

1 reference

title

Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites (English)

1 reference

3 August 2017

1 reference

Carsten Bokemeyer

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Biological Therapy

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

1259-1269

1 reference

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Malignant ascites: systematic review and guideline for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Frequent EpCam protein expression in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Immunotherapy of malignant ascites with trifunctional antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Openings between defective endothelial cells explain tumor vessel leakiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.504706

10.1517/14712598.2010.504706

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference